Lead Product(s): Alprostadil
Therapeutic Area: Cardiology/Vascular Diseases
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Advanz Pharma
Deal Size: $98.0 million Upfront Cash: $84.0 million
Deal Type: Agreement March 06, 2020
The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.